CD37 in acute myeloid leukemia: a novel surface target for drug delivery.

Blood Adv · 2025 · PMC11732606 · PMID 39348689

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendP = .053so close (0.05 < p ≤ 0.1)

We discovered that primary AML samples harboring activating signaling mutations in FLT3, MLL, and KRAS showed a trend toward increased CD37 internalization frequency ( P = .053) compared with those without signaling mutations 8 , 36 ( Figure 2 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.